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ABSTRACT 
Lamellar (component-cell) corneal transplantation is replacing penetrating keratoplasty 
for some corneal disorders in humans; but the relative risks of immunological graft 
rejection for the two procedures are uncertain. A model of component endothelial cell 
keratoplasty (endokeratoplasty) was developed in the outbred sheep. Clinical and 
histological graft outcomes after endokeratoplasty were then compared with 
contemporaneous penetrating corneal allografts. No topical or systemic 
immunosuppression was administered to any recipient sheep. Endothelial cell allografts 
(n = 10) took significantly longer to achieve perfect transparency following surgery than 
did penetrating corneal grafts (n = 7) (day 10 versus day 4; p = 0.003; two-tailed Mann-
Whitney U-test). The median day to rejection of penetrating grafts was post-operative 
day 18; and of endothelial cell grafts was day 48 (p = 0.04; two-tailed Mann-Whitney 
U-test). The clinical courses of the two procedures were quite different. Penetrating 
grafts gained clarity quickly but exhibited rapid graft neovascularization. Clinical 
rejection was preceded by inflammation in the anterior segment. Endothelial cell grafts 
exhibited a fluctuating; more indolent course of opacification; although all did 
eventually fail. Histological analysis confirmed immunological rejection in all failed 
grafts; but with different patterns of leukocytic infiltration in endokeratoplasties 
compared with penetrating keratoplasties. Inflammatory cells in endothelial cell grafts 
were generally fewer in number and were more often found in the posterior stroma. We 
conclude that in the absence of immunosuppression; all endothelial cell allografts do 
undergo immunological rejection; albeit at a slower tempo than penetrating grafts. 
Keywords: corneal transplantation; sheep; endokeratoplasty; immunological rejection 
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INTRODUCTION 
 Corneal transplantation is performed to improve vision, to reduce pain, and for 
emergency structural repair in cases of corneal perforation (25). In penetrating corneal 
transplantation, the full thickness of the cornea is replaced (31). New techniques for 
lamellar (partial thickness) grafts have evolved over recent years, and are now being 
applied to cases that used to be treated by penetrating keratoplasty (1,25). Component 
endothelial cell transplantation, or endokeratoplasty, is a procedure in which the anterior 
portion of the host cornea including the ocular surface is retained, but the posterior 
section including Descemet’s membrane and the corneal endothelium is replaced with 
human donor tissue (20,24). A healthy corneal endothelium, the post-mitotic monolayer 
of cells on the posterior surface of the cornea, is essential for the maintenance of corneal 
transparency (25). The rationale for endokeratoplasty is that in conditions in which only 
the corneal endothelium is dysfunctional or absent, then only this component of the 
cornea needs to be replaced (20). Endokeratoplasty is widely used for bullous 
keratopathy (corneal oedema caused by corneal endothelial cell loss, resulting in pain 
and poor vision) and for Fuchs’ endothelial dystrophy (an adult-onset corneal dystrophy 
caused by corneal endothelial cell dysfunction). These two indications together 
represent one-third of all indications for corneal transplantation (26). 
 The benefits claimed for endokeratoplasty in its various forms are reduced post-
operative suture complications, inflammation and astigmatism, increased wound 
strength, and faster visual rehabilitation compared with penetrating keratoplasty (20,24). 
An important unresolved issue is the extent to which endothelial allografts undergo 
rejection, and therefore the extent to which post-operative topical immunosuppression 
needs to be administered. Many of the essential elements that initiate an allograft 
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response - for example blood vessels, lymphatics, and antigen-presenting cells - are 
located within the corneal stroma (8,25). In penetrating keratoplasty, all of these 
elements are of donor origin, so that the foreign antigenic load is relatively high. Indeed, 
the major cause of the failure of penetrating corneal grafts is irreversible rejection 
(6,26). The anterior chamber, in contrast, is an immune-privileged site in which 
allogeneic skin grafts are not necessarily rejected (10,16,17). Because endothelial grafts 
are placed into the anterior chamber, the pattern of rejection may conceivably differ 
from that seen with penetrating keratoplasty. 
 The outbred sheep is a suitable outbred preclinical model in which to test the 
relative rejection rates of penetrating and component endothelial cell corneal grafts. The 
ovine endothelium is non-replicative, as in humans, and the anatomy of the eye is akin 
to that of the human, with a deep anterior chamber. In the absence of topical, local or 
systemic immunosuppression, penetrating ovine corneal allografts undergo rejection 
several weeks after transplantation in a manner that is similar clinically and 
histologically to corneal allograft rejection in humans (27). We developed a method of 
endokeratoplasty in the sheep that is similar to the procedure known as Descemet’s 
stripping endothelial keratoplasty (DSEK) used in humans (18). We then performed 
contemporaneous ovine penetrating and endothelial cell allografts, to examine the 
macroscopic and histological outcomes, and in particular the relative rates of rejection, 
in the absence of any confounding immunosuppression. 
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MATERIALS AND METHODS 
Animal Ethics 
 All experimentation was performed with approval from the institutional Animal 
Welfare Committee and conformed to the ARVO Statement for the Use of Animals in 
Ophthalmic and Visual Research. Outbred adult cross-bred sheep sourced from a local 
farm were housed indoors, allowed unlimited access to lucerne chaff and water, and 
were examined daily with a hand-held slit-lamp for a week prior to transplantation, to 
accustom them to being handled. Because sheep are herd animals, they were always 
held in groups. 
 
Donor Corneas 
 Ovine eyes were obtained from a local abattoir within 3 hours of death of the 
donor. They were transported on ice to the laboratory, decontaminated in 10% w/v 
povidone-iodine (Sanofi-Aventis, Virginia, QLD, Australia) and washed twice by 
immersion in sterile saline. 
 
Penetrating Keratoplasty in Sheep 
 Penetrating corneal transplantation was performed essentially as previously 
described (27). Recipient sheep (n = 7) were fasted overnight. One eye only of any 
animal was operated upon. One hour prior to surgery, the pupil of the eye to be grafted 
was dilated with topical 1% atropine sulphate (Chauvin Pharmaceuticals, Kingston-
upon-Thames. Surrey, England) and viscous 2.5% phenylephrine hydrochloride 
(Chauvin Pharmaceuticals). Anaesthesia was induced with 25 mg/kg sodium thiopental 
(Abbott Laboratories, North Chicago, IL, USA) delivered intravenously into the 
Copyright © 2012 Cognizant Communication Corporation 
 
CT-0980 Cell Transplantation Epub; provisional acceptance 11/13/2012        6 
 
external carotid vein, and maintained after intubation of the airway with 1.5% isoflurane 
(Veterinary Companies Australia, Kings Park, NSW, Australia) in 2:1 air/oxygen. Local 
anaesthesia with topical 5 mg/ml proxymetacaine hydrochloride (Allergan Australia Pty 
Ltd, Gordon, NSW, Australia) was used as required. A 12 mm diameter donor central 
button was transferred to a 11 mm graft bed. The graft was secured by four interrupted 
9-0 monofilament nylon cardinal sutures (Alcon Australia, Frenchs Forest, NSW, 
Australia) and one continuous 9-0 nylon suture. Prophylactic topical 0.5% 
chloramphenicol (Pfizer Australia Pty Ltd, West Ryde, Australia) was administered to 
the graft once daily for three days post-operatively. Post-operatively, grafts were 
examined each day at the hand-held slit-lamp and scored for clarity, oedema, indices of 
inflammation and the degree of neovascularization of the graft, using a well-validated 
proforma. The onset of corneal graft rejection was defined as inflammation, spreading 
oedema and loss of clarity in a previously thin, clear graft, or the appearance of a 
corneal epithelial or endothelial rejection line. The day of rejection was defined as the 
first day that graft opacity reached 2 on a four-point scale (0 representing transparency, 
4 representing a completely opaque graft), such that the iris margins were no longer 
clearly visible through the graft, or the first day that an endothelial or epithelial rejection 
line was visible in a previously transparent and quiet graft. 
 
Corneal Endothelial Cell Grafts in Sheep 
 Pre-operative treatment and anaesthesia of recipient sheep (n = 10) was exactly 
as for penetrating keratoplasty. The technique used was akin to DSEK in humans 
(18,20,24). A corneo-scleral disc was excised from a donor eye and mounted on an 
artificial anterior chamber (Barron Precision Instruments, Grand Blanc, MI, USA). A 
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thin lamellar graft of posterior stroma and endothelium was fashioned manually from 
the corneo-scleral disc using a Morlet lamellar knife (Duckworth & Kent Ltd, Baldock, 
Hertfordshire, England) and a 12 mm diameter donor graft was cut with a hand-held 
trephine. A 12 mm central disc of Descemet’s membrane and endothelium was removed 
from the recipient sheep by scoring Descemet’s membrane with a reverse Sinskey hook 
(Bausch & Lomb, Macquarie Park, NSW, Australia) and stripping it together with the 
corneal endothelium. The donor disc endothelium was protected by a small amount of 
viscoelastic (Abbott Medical Optics, Pymble, NSW, Australia) and pulled with a 10-0 
prolene suture (Alcon Australia) into the recipient anterior chamber through a 6 mm 
limbal wound on a Sheets glide (Beaver-Visitec International, Waltham, MA, USA). 
The disc was centred and compressed against the defect in the recipient Descemet’s 
membrane for ten minutes with a complete air fill of the anterior chamber. Once the 
graft had adhered  the air was exchanged for ophthalmic Balanced Salt Solution (BSS, 
Alcon Australia) leaving an 8mm bubble of air to tamponade the graft. The wound was 
closed with 3 interrupted 9-0 nylon sutures (Alcon Australia). Post-operatively, grafted 
eyes were observed daily at the hand-held slit-lamp and scored for clarity, oedema, 
indices of inflammation and the degree of corneal neovascularization, as before.  
 
End-point Histology 
 Recipients with failed (oedematous and opaque) corneal grafts were killed by 
overdose of intravenous sodium pentobarbitone and the eyes removed for histological 
analysis. Corneal tissues were fixed in buffered formalin, embedded in paraffin wax, cut 
at 5 µm and stained with Harris’ haematoxylin and eosin. 
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Statistical Analyses 
 Data were analysed by the two-tailed Mann-Whitney U test, corrected for ties, 
with p<0.05 being considered significant. 
RESULTS 
Clinical Outcomes of Ovine Penetrating Corneal Grafts and Corneal Endothelial Cell 
Grafts 
 Penetrating corneal allografts (n = 7) achieved perfect transparency after surgery 
more quickly than did endothelial cell allografts, at a median of 4 days (range 1-6 days) 
for penetrating grafts and 10 days (range 4-31 days for endothelial grafts), p = 0.0034 
(Table 1). Six of seven penetrating grafts underwent rejection at a median of 18 days 
(range 16-29 days) after surgery (Table 1). Graft rejection was accompanied by 
inflammation and neovascularization of the graft, and graft opacity swiftly reached a 
score of 3-4. The one graft that was followed for more than 60 days post-graft 
developed a hyphaema (blood in the anterior chamber) at day 16 and was somewhat 
cloudy from day 25 to day 59, indicative of a rejection episode, although it never 
developed an opacity score of more than 2 and exhibited a fluctuating course. 
 All ovine endokeratoplasties underwent rejection, as assessed by complete 
corneal opacification but at a significantly slower pace than did the penetrating corneal 
grafts, with a median time to rejection of 48 days (range 19->60), p = 0.036 (Table 1). 
 The rejection process in the penetrating and lamellar graft procedures was 
different. Eyes with an endothelial cell graft in situ did not become significantly 
inflamed. The process leading to loss of corneal clarity was often indolent, with 
fluctuating oedema. Keratic precipitates (accumulations of leukocytes) on the graft 
endothelium and small rejection lines became visible at the slit lamp and subsequently 
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disappeared, only to reappear several days later. However, once corneal clarity reached 
a score of more than 2, then complete failure over the following few days was inevitable 
(Fig. 1 A, B). 
Histological Assessment of Grafted Eyes 
 Following euthanasia of recipient sheep, fixed and stained corneal sections were 
examined by a pathologist (SK). Of the 7 penetrating grafts, 6 showed clear evidence of 
rejection, as evidenced by some or all of the following features: central stromal 
neovascularization, infiltration of the limbus, stroma and sometimes epithelium with 
mononuclear cells, mononuclear cells in the anterior chamber, stromal oedema, and 
missing endothelium (Fig. 1C). The exception was the graft that appeared to undergo a 
self-limiting rejection episode but that never completely clouded. This graft showed 
some evidence of corneal neovascularization and a sparse leukocytic infiltrate, but the 
corneal endothelial monolayer appeared intact.  
 Of the 10 endokeratoplasties, three showed evidence of an indolent rejection 
process, marked by deep neovascularization of the stroma, and a slight to moderate 
infiltrate of mononuclear cells. The endothelial monolayer was mostly intact. In a 
further 5 grafts, the evidence of rejection was more pronounced (Fig. 1D), as for the 
penetrating grafts, with mononuclear cells in the anterior chamber and attached to the 
corneal endothelium. A leukocytic infiltrate was apparent both in the residual deep 
posterior stroma of the recipient, as well as in the graft, suggesting infiltration from the 
limbus. Several of the rejected penetrating grafts exhibited semi-organised 
accumulations of lymphoid cells that resembled germinal centres at the limbus (Fig. 1E) 
of the recipient cornea, but these aggregates were not observed in the 
endokeratoplasties. 
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DISCUSSION 
The early outcomes of penetrating corneal allotransplantation are typically excellent and 
graft survival figures of 90% at one year after surgery are not uncommon. However, 
inspection of corneal transplant registry data shows that Kaplan-Meier survival of 
penetrating corneal allografts at 15 years is 55% and irreversible rejection is the most 
important cause of penetrating corneal graft failure (6,8,28). One of the potential 
benefits of the alternative surgical procedure of endokeratoplasty is that rejection may 
be less of a concern than for penetrating keratoplasty (2,4). However, we found that in 
the absence of any topical or other immunosuppression, all of the ovine endothelial cell 
grafts in our series underwent rejection, albeit at a slower tempo than did 
contemporaneous penetrating grafts. 
 Clinical experience with endothelial keratoplasty, as with penetrating 
keratoplasty, is almost always performed against a background of topical 
immunosuppression with glucocorticosteroids (6). Under these circumstances, the mean 
likelihood of a rejection episode (reversible or irreversible) in an endothelial graft is 
approximately 9% (range: >1–36%), depending on co-morbidities such as glaucoma, 
the type of endokeratoplasty, and the length of follow-up (2,3,4,7,9,12,13,15,21,23,29). 
Price et al. estimated that the probability of a rejection episode in a DSEK was 7.6% by 
1 year and 12% by 2 years post-operatively (19). A review from the American Academy 
of Ophthalmology in 2009 reported an endothelial graft rejection of 10% (range: 0%-
45%) for DSEKs (14). The corresponding figure for penetrating grafts is approximately 
18% for all indications over 20 years (26), but no human endokeratoplasties have as yet 
been followed for this length of time, and comparative studies in humans have generally 
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been retrospective rather than contemporaneous. Further, in some centres patients with 
endothelial grafts are prescribed topical steroids for longer periods than are patients 
with penetrating grafts (2). It is thus difficult to compare the rejection rates in the two 
types of procedure. 
 Animal studies are few, but a recent report compared outcomes of penetrating 
grafts and endothelial grafts in rabbits over a time-frame of one month following 
surgery (11). There were no rejection reactions in the endothelial grafts over this time, 
whereas half of the penetrating grafts suffered a rejection episode, and the authors of the 
study concluded that the former exhibited a lower rate of rejection than the latter. The 
work we report here in the sheep suggests that in the absence of topical 
immunosuppression, the tempo of rejection may differ between the two procedures but 
the final incidence of rejection, of severity sufficient to cause graft failure, is the same. 
The lesser antigen load associated with endokeratoplasty does not prevent sensitization 
from occurring, and once sensitization has occurred, the graft will fail. 
 The clinicopathologic correlates and signs of immunological rejection in ovine 
endokeratoplasties included corneal neovascularization, diffuse stromal oedema, keratic 
precipitates on the endothelium, and in some cases Khodadoust lines, similar to the 
pattern seen in rejecting human endokeratoplasties (12). At a histopathological level, 
failed human component cell grafts have been reported to exhibit evidence of stromal 
inflammation (22) and corneal endothelial cell loss (30), but specimens are rarely 
available during or immediately following an irreversible rejection episode. Here, we 
showed that decompensated ovine corneas collected shortly after onset of rejection 
displayed deep corneal neovascularization together with a variable degree of leukocytic 
infiltrate in the posterior stroma and the anterior chamber. As expected from previous 
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work, rejected penetrating grafts showed a more substantial infiltrate throughout the 
cornea, including in the epithelium, and neovascularization was more evenly distributed 
throughout the stroma (27). Of note, in several instances we observed organizing 
lymphoid aggregates with the appearance of a germinal centre at the limbus, 
reminiscent of conjunctiva-associated lymphoid tissue. Similar findings have previously 
been reported by others in the rat (5), but are unlikely to be seen in humans because 
peripheral tissue is not available for histology, even after graft failure. 
 In the absence of immunosuppressive cover, both penetrating and endothelial 
ovine allografts undergo rejection, albeit with different kinetics. However, once the 
rejection process has reached a particular stage or tipping-point, roughly correlating 
with corneal opacity of a degree that renders the iris margins indistinct through the 
graft, then the effector arm of the immune response swiftly leads to decompensation, 
irrespective of the type of graft. We speculate that the different tempi of the initial 
rejection responses may result from delayed sensitization, in the case of the component 
cell grafts, perhaps reflecting slower neovascularization of the graft, or less alloantigen 
finding its way in cell-bound or cell-free form to the secondary lymphoid tissue or to 
conjunctiva-associated lymphoid tissue. 
 What are the implications for human corneal grafts? Sensitisation to corneal 
endothelial cell-derived foreign alloantigen is very likely to occur eventually, especially 
if the recipient is at moderate to high risk of rejection by virtue of co-morbidity such as 
corneal neovascularization. Topical immunosuppression may need to be continued in 
the longer term. 
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FIGURE LEGEND 
 
Figure 1. Outcomes of keratoplasty in the sheep. Clinical photographs: A-B. (A) 
Transparent endokeratoplasty at day 41 post-graft. (B) Same eye as in (A) at day 48 
post-graft: the cornea is opacifying and the graft failing. Representative histology (H&E 
sections) of rejected penetrating keratoplasty and endokeratoplasty: C-D, scale bars 
represent 100 m. (C) Endothelial rejection in an eye with a penetrating graft. (D) 
Endothelial rejection in an eye with a corneal endothelial cell graft. (E) Semi-organised 
lymphoid follicle at limbus in eye with a rejected penetrating corneal graft.  
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TABLE 1. Clinical outcomes of ovine penetrating corneal allografts and of endokeratoplasties 
 
Type of keratoplasty Number Day first completely transparent Median Day of rejection       Median 
____________________________________________________________________________________________________________________ 
Penetrating  7  1, 3, 4, 4, 4, 5, 6   4  16, 18, 18, 18, 25, 29, >60      18 
Endokeratoplasty 10  4, 6, 6, 7, 10, 10, 13, 15, 21, 31 10*  19, 26, 36, 42, 45, 51, 59, 61, 76, 85     48** 
____________________________________________________________________________________________________________________ 
* comparison between penetrating keratoplasty and endokeratoplasty: p = 0.0034 
** comparison between penetrating keratoplasty and endokeratoplasty: p = 0.036 
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